



## Original Investigation | Global Health

# Factors Associated With Household Transmission of SARS-CoV-2 An Updated Systematic Review and Meta-analysis

Zachary J. Madewell, PhD; Yang Yang, PhD; Ira M. Longini Jr, PhD; M. Elizabeth Halloran, MD, DSc; Natalie E. Dean, PhD

# **Abstract**

**IMPORTANCE** A previous systematic review and meta-analysis of household transmission of SARS-CoV-2 that summarized 54 published studies through October 19, 2020, found an overall secondary attack rate (SAR) of 16.6% (95% CI, 14.0%-19.3%). However, the understanding of household secondary attack rates for SARS-CoV-2 is still evolving, and updated analysis is needed.

**OBJECTIVE** To use newly published data to further the understanding of SARS-CoV-2 transmission in the household.

**DATA SOURCES** PubMed and reference lists of eligible articles were used to search for records published between October 20, 2020, and June 17, 2021. No restrictions on language, study design, time, or place of publication were applied. Studies published as preprints were included.

**STUDY SELECTION** Articles with original data that reported at least 2 of the following factors were included: number of household contacts with infection, total number of household contacts, and secondary attack rates among household contacts. Studies that reported household infection prevalence (which includes index cases), that tested contacts using antibody tests only, and that included populations overlapping with another included study were excluded. Search terms were *SARS-CoV-2* or *COVID-19* with secondary attack rate, household, close contacts, contact transmission, contact attack rate, or family transmission.

**DATA EXTRACTION AND SYNTHESIS** Meta-analyses were performed using generalized linear mixed models to obtain SAR estimates and 95% Cls. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed.

**MAIN OUTCOMES AND MEASURES** Overall household SAR for SARS-CoV-2, SAR by covariates (contact age, sex, ethnicity, comorbidities, and relationship; index case age, sex, symptom status, presence of fever, and presence of cough; number of contacts; study location; and variant), and SAR by index case identification period.

**RESULTS** A total of 2722 records (2710 records from database searches and 12 records from the reference lists of eligible articles) published between October 20, 2020, and June 17, 2021, were identified. Of those, 93 full-text articles reporting household transmission of SARS-CoV-2 were assessed for eligibility, and 37 studies were included. These 37 new studies were combined with 50 of the 54 studies (published through October 19, 2020) from our previous review (4 studies from Wuhan, China, were excluded because their study populations overlapped with another recent study), resulting in a total of 87 studies representing 1249 163 household contacts from 30 countries. The estimated household SAR for all 87 studies was 18.9% (95% CI, 16.2%-22.0%). Compared with studies from January to February 2020, the SAR for studies from July 2020 to March 2021 was higher (13.4% [95% CI, 10.7%-16.7%] vs 31.1% [95% CI, 22.6%-41.1%], respectively). Results from

(continued)

## **Key Points**

**Question** Are early estimates of household transmission of SARS-CoV-2 indicative of current household transmission?

Findings In this updated systematic review and meta-analysis of 87 studies representing 1249 163 household contacts from 30 countries, the estimated household secondary attack rate was 19%. An increase in household transmission was observed over time, perhaps owing to improved diagnostic procedures and tools, longer follow-up, more contagious variants, and different study locations.

Meaning These findings suggest that the household remains an important site of SARS-CoV-2 transmission, and recent studies have generated higher household secondary attack rate estimates compared with the earliest reports; more transmissible variants and vaccines may be associated with additional changes in the future.

## + Supplemental content

Author affiliations and article information are listed at the end of this article

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

subgroup analyses were similar to those reported in a previous systematic review and meta-analysis; however, the SAR was higher to contacts with comorbidities (3 studies; 50.0% [95% CI, 41.4%-58.6%]) compared with previous findings, and the estimated household SAR for the B.1.1.7 (a) variant was 24.5% (3 studies; 95% CI, 10.9%-46.2%).

**CONCLUSIONS AND RELEVANCE** The findings of this study suggest that the household remains an important site of SARS-CoV-2 transmission, and recent studies have higher household SAR estimates compared with the earliest reports. More transmissible variants and vaccines may be associated with further changes.

JAMA Network Open. 2021;4(8):e2122240. doi:10.1001/jamanetworkopen.2021.22240

## Introduction

Understanding of the household secondary attack rate for SARS-CoV-2 is still evolving. We previously published a systematic review and meta-analysis of household transmission of SARS-CoV-2 that summarized 54 published studies representing 77 758 household contacts through October 19, 2020, finding an overall secondary attack rate (SAR) of 16.6% (95% CI, 14.0%-19.3%). Household SARs were higher to adult contacts than to child contacts, to spouses than to other contacts, from symptomatic index cases than from asymptomatic index cases, and in households with 1 contact than in households with 3 or more contacts. The SARs were higher to household contacts than to other close contacts. Household SARs were also higher for SARS-CoV-2 than for SARS-CoV and Middle East respiratory syndrome coronavirus. This living systematic review and meta-analysis updated those findings through June 17, 2021, and used newly published data to further our understanding of the household's role in SARS-CoV-2 transmission. <sup>2</sup>

## **Methods**

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline using the same definitions, search strategy, eligibility criteria, and data extraction methods used in our original study. We searched PubMed and reference lists of eligible articles for studies published between October 20, 2020, and June 17, 2021, with no restrictions on language, study design, time, or place of publication. Studies published as preprints were included. Search terms were SARS-CoV-2 or COVID-19 with secondary attack rate, household, close contacts, contact transmission, contact attack rate, or family transmission.

Articles with original data that reported at least 2 of the following factors were included: number of household contacts with infection, total number of household contacts, and secondary attack rates among household contacts. Studies that reported household infection prevalence (including index cases), that tested contacts using antibody tests only, and that included populations that overlapped with another included study were excluded.

In addition to the covariates examined previously, we also examined SAR by contact ethnicity (restricted to studies in the US), contact comorbidity, index case fever, index case cough, and variant (if reported in  $\geq$ 3 studies). Primary outcomes were overall household SAR for SARS-CoV-2, SAR by covariates (contact age, sex, ethnicity, comorbidities, and relationship; index case age, sex, symptom status, presence of fever, and presence of cough; number of contacts; study location; and variant), and SAR by index case identification period. We categorized contact and index case age as adults (aged  $\geq$ 18 years) and children (aged <18 years). For studies that reported SARs by age using 10-year increments (eg, 10-19 years), we included those aged 18 and 19 years in the child category. For the symptom status of the index case covariate, we included studies that disaggregated SARs for at least

## JAMA Network Open | Global Health

2 of the following: symptomatic, presymptomatic, and asymptomatic individuals. We also conducted a sensitivity analysis restricted to studies with a more uniform design, which excluded studies with only asymptomatic or pediatric index cases, studies that tested only symptomatic or asymptomatic contacts, studies with long follow-up periods (≥21 days), and studies published as preprints.

In addition, to examine temporal patterns, we assessed household SARs by index case identification period (January-February 2020, March-April 2020, May-June 2020, and July 2020-March 2021). If the study period spanned multiple months, we used the midpoint. For example, when the index case identification period for all households was December 2019 to April 2020, the midpoint was February 2020, and the study was categorized as January to February 2020.

## **Statistical Analysis**

Statistical analyses were similar to those previously described. However, this analysis used generalized linear mixed models to obtain SAR estimates and 95% CIs; these models appear to be more robust for meta-analyses of single proportions compared with Freeman-Tukey double arcsine transformation. Heterogeneity was measured using the  $l^2$  statistic, with thresholds of 25%, 50%, and 75% indicating low, moderate, and high heterogeneity, respectively. All analyses were performed using the metafor package in R software, version 4.0.2 (R Foundation for Statistical Computing). Statistical significance was set at 2-tailed P = .05.

## **Results**

We identified 2722 records (2710 records from database searches and 12 records from the reference lists of eligible articles) published between October 20, 2020, and June 17, 2021; of those, 93 fulltext articles reporting household secondary transmission of SARS-CoV-2 were assessed for eligibility, and 37 studies<sup>4-40</sup> were eligible for inclusion (3 of these studies were preprints that were identified in our previous review and subsequently published) (Figure 1; eTable 1 in the Supplement). These 37 new studies were combined with 50 of the 54 studies (published through October 19, 2020) included in our previous review (4 studies<sup>41-44</sup> from Wuhan, China, were excluded because their study populations overlapped with another recent study), <sup>14</sup> resulting in 87 total studies <sup>4-40,45-94</sup> representing 1249 163 household contacts from 30 countries. The estimated overall household SAR for all 87 studies was 18.9% (95% CI, 16.2%-22.0%), with significant heterogeneity ( $l^2 = 99.4\%$ ; P < .001) (Figure 2). Excluding studies with only asymptomatic<sup>85</sup> or pediatric<sup>36,66</sup> index cases, studies that tested only<sup>7,9,15,17,19,24,26,29-31,35,37,45,47,61,65,68,69,71,77,79,81,82,86,87,90,92,94</sup> or asymptomatic<sup>78</sup> contacts, studies with long follow-up periods (≥21 days), <sup>5,8,9,23,46,92</sup> and studies published as preprints, 8,23,24,29,45,79,88-90,92 the overall SAR among the 47 remaining studies<sup>4,6,10-14,16,18,20-22,25,27,28,32-34,38,39,48-55,57-60,62-64,67,70,72-76,80,83,84,91,93</sup> was 19.9% (95% CL 16.2%-24.2%).

When analyzing household SAR by study period, we observed an increasing pattern over time. Compared with the SAR for 28 studies  $^{12,14,17,27,45-67,94}$  from January to February 2020 (13.4%; 95% CI, 10.7%-16.7%), the SAR was significantly higher for 30 studies  $^{6,7,15,16,19,22,25,26,28,30,68-86,93}$  from March to April 2020 (19.4%; 95% CI, 15.2%-24.5%; P = .03) and 15 studies  $^{5,8,10,18,20,21,23,24,29,31,32,35,37,38,40}$  from July 2020 to March 2021 (31.1%; 95% CI, 22.6%-41.1%; P < .001) but not significantly different from the SAR for 14 studies  $^{4,9,11,13,33,34,36,39,87-92}$  from May to June 2020 (19.9%; 95% CI, 13.0%-29.3%; P = .07) (**Figure 3** $^{14}$ ). To elucidate factors associated with differences in SAR, we explored attributes of studies from the periods with the lowest and highest household SARs. Among 28 studies  $^{12,14,17,27,45-67,94}$  from January to February 2020 and 15 studies  $^{5,8,10,18,20,21,23,24,29,31,32,35,37,38,40}$  from July 2020 to March 2021, 6 studies  $^{12,46,54,57,59,62}$  (21.4%) and 4 studies  $^{8,10,20,23}$  (25.0%), respectively, reported testing contacts at least twice, 1 study  $^{46}$  (3.6%) and 3 studies  $^{5,8,23}$  (18.8%) reported following contacts for longer than 14 days, 1 study  $^{45}$  (3.6%) and 6 studies  $^{8,23,24,29,37,40}$  (33.3%) were published as preprints, 21 studies  $^{12,14,27,46,48-55,57-60,62-64,66,67}$  (75.0%) and 10 studies  $^{5,8,10,18,20,21,23,32,38,40}$  (66.6%) tested all


contacts regardless of symptoms, and O studies and 3 studies <sup>18,35,40</sup> (18.8%) reported SARs for variants of concern (VOCs).

The SARs were significantly higher for adult contacts (29.9%; 95% CI, 24.0%-36.6%) than for child contacts (17.5%; 95% CI, 12.6%-23.7%;

P < .001), <sup>7,8,11,13-15,26,30,32,35,40,45,46,50,54,60,70-73,75,87,88,91</sup> for spousal contacts (39.8%; 95% CI, 30.0%-50.5%) than for other household contacts (18.3%; 95% CI, 12.1%-26.7%; P = .001), <sup>8,11,17,30,33,46,47,52,72,93,95</sup> for contacts with comorbidities (50.0%; 95% CI, 41.4%-58.6%) than for contacts without comorbidities (22.0%; 95% CI, 13.4%-33.9%; P = .04), <sup>30,45,46</sup> in symptomatic index cases (20.2%; 95% CI, 13.9%-28.3%) <sup>6,13,14,16,24,27,58,93</sup> than in asymptomatic (3.0%; 95% CI, 1.7%-5.4%) <sup>6,14,24,27,58,93</sup> or presymptomatic (8.1%; 95% CI, 7.3%-9.1%;

P < .001)<sup>24,58,93</sup> index cases, and in households with 1 contact (35.5%; 95% CI, 26.2%-46.2%) than in households with 3 or more contacts (21.2%; 95% CI, 14.8%-29.4%;

P = .02)<sup>11,16,30,32,40,41,45,46,70,81,88</sup> (**Table**). The SARs were not associated with the contact's sex<sup>8,11,13-15,17,26,28,30,33,40,45-47,52,54,72,81,84,88,91</sup> or ethnicity<sup>11,18,72</sup> or with the index case's age, <sup>11,13,14,16,24,32,35,57,91</sup> sex, <sup>11,13,14,16,24,32,46,52,72,81,84,91</sup> presence of fever, <sup>11,46,52</sup> or presence of cough. <sup>11,46,52</sup> When the analysis was restricted to laboratory-confirmed results, <sup>30,45,46</sup> the estimated SAR to contacts with comorbidities was 43.9% (95% CI, 32.1%-56.5%). The estimated mean SAR for the B.1.1.7 (a) variant was 24.5% (95% CI, 10.9%-46.2%), <sup>35,40,96</sup> with significant heterogeneity



 $(P^2 = 99.5\%; P < .001)$  (eFigure in the Supplement). Restricting the analysis to studies with a more uniform design, <sup>11,16,32,70</sup> SARs were not significantly different for the number of contacts in the household (P = .51) (eTable 2 in the Supplement). No studies with data regarding the comorbidity covariate met the criteria for inclusion in this subanalysis.

## **Discussion**

This updated systematic review and meta-analysis found that, with the addition of 37 studies, <sup>4-40</sup> the estimated overall household SAR of SARS-CoV-2 was 18.9%, which is similar to the estimate in the previous review. <sup>1</sup> Nonetheless, when analyzing SAR by study period, we observed an increase in household transmission over time. Potential explanations for this temporal pattern include improved diagnostic procedures and tools, longer follow-up (which may have captured tertiary transmission or transmission from nonhousehold contacts), more contagious variants, and different study locations. We found lower SARs in studies from China and Singapore, <sup>17,84,97</sup> potentially owing to mandated quarantine policies. It is also conceivable that the higher SARs observed may be a reflection of publication and time-trend biases, which can impact the generalizability of living systematic reviews. <sup>98</sup>

Results from the subgroup analyses reported in our previous systematic review and meta-analysis<sup>1</sup> remained largely similar, with a few exceptions. We observed higher transmission to contacts with comorbidities across 3 studies. <sup>30,45,46</sup> Two of these studies<sup>30,45</sup> tested only symptomatic contacts. It is possible that testing was more common among symptomatic contacts with comorbidities. <sup>99</sup> Individuals with comorbidities may also be more susceptible to SARS-CoV-2




Figure 2. Household Secondary Attack Rates by Study Location

For studies that included data from multiple regions within a country, a point in the center of the country was selected. Circle sizes represent extent of secondary attack rates, with small circles indicating 0.2, medium circles indicating 0.4, and large circles indicating 0.6.

0.8 SAR (95% CI) 0.4 0.6 0.2 0.04 (0.00-0.18) 0.04 (0.00-0.11) 0.19 (0.15-0.25) 0.53 (0.46-0.60) 0.48 (0.42-0.55) 0.39 (0.33-0.45) 0.31 (0.29-0.35) 0.20 (0.21-0.38) 0.26 (0.21-0.38) 0.17 (0.11-0.18) 0.13 (0.09-0.18) 0.11 (0.11-0.11) 0.09 (0.08-0.10) 0.09 (0.06-0.12) 0.03 (0.02-0.04) 0.13 (0.11-0.15) 0.10 (0.10-0.10) 0.31 (0.23-0.41) 0.67 (0.58-0.76) 0.63 (0.58-0.69) 0.56 (0.48-0.63) 0.46 (0.31-0.62) 0.10 (0.10-0.11) 0.08 (0.05-0.12) 0.35 (0.33-0.37) 0.25 (0.24-0.26) 0.21 (0.20-0.21) 0.19 (0.19-0.20) .06-0.28) 0.11 (0.07-0.15) 0.06 (0.03-0.10) 0.20 (0.13-0.29) 0.19 (0.16-0.22) 0.15 (0.11-0.19) 0.14 (0.13-0.15) 0.12 (0.08-0.17) 0.11 (0.06-0.18) 0.11 (0.09-0.14) 0.11 (0.09-0.13) 0.13 (0.05-0.25) 0.44 (0.32-0.56) 27-0.47) (0.12-0.31)SAR (95% CI) 0.37 (0.2 19443 174 106 745 780 264 17917 16612 Total 3546 191 223 246 989 989 130 108 849 849 2226 144 2381 196 265 23 46 39 89 Infected 16404 21 12 83 83 28 1809 16 116 66 200 98 18 18 28 34 839 839 283 4133 4030 102 108 95 314 40 31 221 371 24 6 380 14 44 Netherlands and Belgium Northern Ireland South Korea South Korea Bangladesh Singapore Thailand Australia Denmark Portugal Germany Denmark Malaysia Brunei Norway Greece France Poland Canada Japan Spain Egypt dentified March-April 2020 (continued) India Italy India ran NS NS US nS nS Fateh-Moghadam et al, <sup>79</sup> 2020 Islam and Noman et al, 89 2020 dentified July 2020-March 2021 Sundar and Bhaskar, 21 2021 Arnedo-Pena et al, <sup>81</sup> 2020 Malheiro et al, <sup>82</sup> 2020 Laxminarayan et al, 91 2020 Jashaninejad et al, 33 2021 Charbonnier et al, <sup>36</sup> 2021 Phiriyasart et al, 80 2020 dentified May-June 2020 Loenenbach et al, <sup>35</sup> 2021 Wilkinson et al, <sup>26</sup> 2021 Semakula et al, 39 2021 Teherani et al,87 2020 Grijalva et al, <sup>11</sup> 2020 Koureas et al, 13 2021 Draper et al, 86 2020 Adamik et al, 90 2020 Lyngse et al,88 2020 Metlay et al, <sup>15</sup> 2021 Gomaa et al, <sup>10</sup> 2021 Lyngse et al, <sup>40</sup> 2021 Verberk et al, 37 202 Akaishi et al, 38 2021 Areekal et al, 4 2021 Fanaka et al, 23 2021 Yung et al, 84 2020 Chaw et al, <sup>93</sup> 2020 Vallès et al, 34 2021 Demko et al, 9 2021 subgroup estimate Subgroup estimate Shah et al, <sup>92</sup> 2020 Subgroup estimate Cerami et al, 8 2021 Peng et al, <sup>18</sup> 2021 Kuba et al, <sup>30</sup> 2021 Son et al, 83 2020 Reid et al, 20 2021 Lee et al, 85 2020 Hsu et al, <sup>31</sup> 2021 Harris, 29 2021 1.0 0.4 0.6 0.8 Figure 3. Household Secondary Attack Rates by Midpoint of Index Case Identification Period SAR (95% CI) 0.2 0.00 (0.00-0.02) 0.32 (0.25-0.40) 0.32 (0.28-0.38) 0.21 (0.07-0.40) 0.20 (0.16-0.26) 0.18 (0.16-0.21) 0.18 (0.14-0.23) 0.18 (0.11-0.26) 0.18 (0.14-0.23) 0.17 (0.13-0.22) 0.17 (0.14-0.20) 0.16 (0.08-0.26) 0.16 (0.16-0.16) 0.16 (0.13-0.18) 0.15 (0.11-0.20) 0.14 (0.12-0.15) 0.13 (0.07-0.21) 0.12 (0.11-0.12) 0.11(0.09-0.14)0.11 (0.00-0.29) 0.10 (0.09-0.12) 0.10 (0.08-0.12) 0.08 (0.03-0.13) 0.07 (0.07-0.08) 0.07 (0.06-0.08) 0.07 (0.03-0.11) 0.06 (0.05-0.07) 0.13(0.11-0.17)0.74 (0.62-0.84) 0.43 (0.36-0.50) 0.41 (0.35-0.47) 0.38 (0.33-0.43) 0.35 (0.30-0.41) 0.32 (0.30-0.34) 0.30 (0.29-0.31) 0.29 (0.16-0.43) 0.28 (0.21-0.34) 0.27 (0.21-0.34) 0.25 (0.15-0.36) 0.23 (0.19-0.28) 0.22 (0.15-0.29) 0.21 (0.03-0.47) 0.19 (0.16-0.22) 0.18 (0.13-0.24) 0.17 (0.12-0.22) SAR (95% CI) 225 2441 93 10592 52822 Total 1015 9606 1021 272 106 280 267 542 989 119 343 289 42 188 174 64 335 132 14 14 775 200 230 19 62 Infected 1248 8447 111 34 105 3 151 104 19 49 46 93 10 10 12 4 2 12 16 29 US Netherlands South Korea South Korea South Korea South Korea South Korea Germany Canada China China Italy dentified January-February 2020 van der Hoek et al, 73 2020a Doung-Ngern et al, 78 2020 Boscolo-Rizzo et al, <sup>69</sup> 2020 Lopez Bernal et al, 45 2020 dentified March-April 2020 Rosenberg et al, 70 2020 Korea CDC et al, 94 2020 Miyahara et al, 16 2021a Böhmer et al, <sup>48</sup> 2020 Dong et al, <sup>49</sup> 2020<sup>a</sup> Dattner et al, 71 2021 Dawson et al, 74 2021 Burke et al, <sup>61</sup> 2020 Luo et al, <sup>62</sup> 2020 Zhuang et al,64 2020 Wang et al, <sup>56</sup> 2020 Park et al, <sup>58</sup> 2020 Zhang et al, <sup>67</sup> 2020a Trunfio et al, 25 2021 Zhang et al, 55 2020 Cheng et al, 65 2020 7 2021 Chen et al, <sup>51</sup> 2020<sup>a</sup> Bender et al,<sup>6</sup> 2021 Lewis et al, 72 2020 Wang et al, 75 2020 Patel et al, <sup>68</sup> 2020 Subgroup estimate Sun et al, <sup>47</sup> 2020a Jing et al, <sup>54</sup> 2020 Seto et al, 28 2021 Hua et al, <sup>50</sup> 2020<sup>a</sup> Park et al, 57 2020 Liu et al, <sup>59</sup> 2020<sup>a</sup> Wu et al, <sup>27</sup> 2021<sup>a</sup> Kim et al, <sup>66</sup> 2021 Wu et al, <sup>53</sup> 2020 Kin et al, <sup>52</sup> 2021 Tak et al, 22 2021 Hu et al, <sup>12</sup> 2021 Li et al, <sup>14</sup> 2021 Bi et al, <sup>60</sup> 2020 Hu et al, <sup>63</sup> 2021 Ng et al, <sup>17</sup> 2021 Han, 76 2020 Carazo et al,

categorized as January 2020. The meta-analysis excluded 4 studies from Wuhan, China, 41-44 that had overlapping populations with Li et al. 14 Point sizes are an inverse function of the precision of the estimates, and bars For studies that spanned multiple months, the midpoint was used. For example, when the index case identification period for all households was December 2019 to April 2020, the midpoint was February 2020, and the study was correspond to 95% Cls. Diamonds represent summary SAR estimates with corresponding 95% Cls.

<sup>a</sup> Study included family contacts, which may have comprised individuals outside the household.

Characteristic	Studies, No.	SAR, % (95% CI)
Measures used for overall SAR	Studies, No.	3AN, 70 (3370 CI)
assessment		
Laboratory-confirmed results plus probable untested symptomatic cases	874-40,45-94a	18.9 (16.2-22.0)
Laboratory-confirmed results only	81 <sup>4-6,8-18,20-23,25-40,45-67,69-80,82-86,88-94a</sup>	18.1 (15.4-21.3)
Contact age		
Adults (≥18 y)	24 <sup>7,8,11,13-15,26,30,32,35,40,45,46,50,54,60,70-73,75,87,88,91b</sup>	29.9 (24.0-36.6)
Children (<18 y)	24 <sup>7,8,11,13-15,26,30,32,35,40,45,46,50,54,60,70-73,75,87,88,91b</sup>	17.5 (12.6-23.7)
Contact sex		
Female	218,11,13-15,17,26,28,30,33,40,45-47,52,54,72,81,84,88,91b	22.4 (17.4-28.5)
Male	218,11,13-15,17,26,28,30,33,40,45-47,52,54,72,81,84,88,91b	20.2 (15.2-26.4)
Contact ethnicity <sup>c</sup>		· , ,
Hispanic or Latino	3 <sup>11,18,72</sup>	36.0 (16.7-61.2)
Non-Hispanic or non-Latino	3 <sup>11,18,72</sup>	36.4 (25.7-48.8)
Contact comorbidities		(
Any	330,45,46	50.0 (41.4-58.6)
None indicated	330,45,46	22.0 (13.4-33.9)
Relationship to index case		22.0 (23.1 33.3)
Spouse	118,11,17,30,33,46,47,52,72,93,95	39.8 (30.0-50.5)
Other	118,11,17,30,33,46,47,52,72,93,95	18.3 (12.1-26.7)
Index case age		10.5 (12.1 20.7)
Adult (≥18 y)	η11,13,14,16,24,32,35,57,91	22.7 (15.2-32.6)
Child (<18 y)	q11,13,14,16,24,32,35,57,91	18.5 (11.8-27.7)
Index case sex	<b>3</b> · · · · · · · ·	10.3 (11.0-27.7)
Female	1711,13,14,16,24,32,46,52,72,81,84,91b	22.2 (15.0.20.5)
	12 1,13,14,16,24,32,46,52,72,81,84,91b	22.3 (15.8-30.5)
Male	12-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	21.3 (15.1-29.2)
Index case symptom status <sup>d</sup>	86,13,14,16,24,27,58,93	20.2 (12.0.20.2)
Symptomatic	66,14,24,27,58,93	20.2 (13.9-28.3)
Asymptomatic		3.0 (1.7-5.4)
Presymptomatic	324,58,93	8.1 (7.3-9.1)
Asymptomatic and/or presymptomatic Index case fever	86,13,14,16,24,27,58,93	3.9 (2.1-6.8)
Yes	311,46,52	20.6 (12.2-32.7)
No	311,46,52	
	3 / /	14.7 (10.6-19.9)
Index case cough	311,46,52	22 7 /11 2 40 2
Yes	311,46,52	22.7 (11.3-40.3)
No Contacts in household, No	J	17.3 (13.9-21.4)
Contacts in household, No.	1111,16,30,32,40,41,45,46,70,81,88	25 5 (20 2, 40 2)
1		35.5 (26.2-46.2)
2	1111,16,30,32,40,41,45,46,70,81,88	31.8 (20.4-45.9)
≥3	1111,16,30,32,40,41,45,46,70,81,88	21.2 (14.8-29.4)
Location	2212 14 17 27 46 47 40-56 50 60 62-64 67 75 842	
China or Singapore	2212,14,17,27,46,47,49-56,59,60,62-64,67,75,84a	14.4 (11.8-17.4)
Other	65 <sup>4-11,13,15,16,18-26,28-40,45,48,57,58,61,65,66,68-74,76-83,85-94</sup>	20.7 (17.0-24.9)
Testing protocol <sup>e</sup>		
Symptomatic and asymptomatic individuals	57 <sup>4</sup> -6,8,10-14,16,18,20-23,25,27,28,32-34,36,38-40,46,48-55,57-60,62-64,66,67,70,72-76,80,83-85,88,89,91,93a	19.8 (16.1-24.1)
Symptomatic individuals only	28 <sup>7</sup> ,9,15,17,19,24,26,29-31,35,37,45,47,61,65,68,69,71,77,79,81,82,86,87,90,92,94a	17.5 (13.6-22.1)
Index case identification period excluding overlapping dates		
December 2019-April 2020	52 <sup>6</sup> ,12,14,17,19,22,25-27,45-70,72-86,93,94a	15.8 (13.0-19.1)
July 2020-March 2021	144,5,18,20,21,23,24,29,33-36,38,88	27.7 (20.6-36.2)

(continued)

Table. Characteristics of Studies Included in Analysis of Household Secondary Attack Rates for SARS-CoV-2 (continued)

Characteristic	Studies, No.	SAR, % (95% CI)
Study published as preprint		
Yes	128,23,24,29,37,40,45,79,88-90,92	21.0 (13.8-30.6)
No	75 <sup>4-7,9-22,25-28,30-39,46-72,74-78,80-87,91,93,94</sup>	18.6 (15.7-21.9)
Restriction to studies testing all contacts at least twice	15 <sup>8,10-12,20,23,34,39,46,54,57,59,62,73,80b</sup>	26.2 (16.5-39.0)
Restriction to studies with long follow-up duration (≥21 d)	65,8,9,23,46,92	32.3 (18.0-51.0)
Proportion of households with any secondary transmission	15 <sup>7-9,13,17,26,30,37,46,70,72,75,84,86,92</sup>	35.0 (22.8-49.6)

Abbreviation: SAR, secondary attack rate.

- $^{\rm a}$  Excludes 4 studies  $^{\rm 41-44}$  from Wuhan, China, that had populations overlapping with Li et al  $^{\rm 14}$
- <sup>b</sup> Excludes 1 study<sup>44</sup> from Wuhan, China, that had populations overlapping with Li et al. <sup>14</sup>
- <sup>c</sup> Restricted to studies in the US.

- d Restricted to studies that disaggregated SARs for at least 2 of the followingsymptomatic, presymptomatic, and asymptomatic individuals.
- <sup>e</sup> Excludes 2 studies, <sup>56,78</sup> 1 in which the testing protocol could not be determined <sup>56</sup> and 1 in which only asymptomatic contacts received testing. <sup>78</sup>

infection via a number of molecular mechanisms. 100 For example, Metlay et al 15 reported that SARs were highest to household contacts with liver disease (25.5%), kidney disease (24.0%), and hypertension (21.6%). There was also a higher estimate of transmission from asymptomatic or presymptomatic index cases across 8 total studies<sup>6,13,14,16,24,27,58,93</sup> compared with the transmission found in the previous meta-analysis, <sup>1</sup> although this transmission remained considerably lower than transmission from symptomatic index cases. Studies of household transmission frequently combine these groups; however, another systematic review<sup>101</sup> that included nonhousehold contacts reported higher transmission from presymptomatic index cases (7%; 95% CI, 3%-11%; 11 studies) than from asymptomatic index cases (1%; 95% CI, 0%-2%; 10 studies). Presymptomatic SAR is based on overall exposure before symptom onset, and presymptomatic exposure is usually of substantially shorter duration than symptomatic exposure. Most studies reporting SARs from symptomatic index cases have not separated the different phases of exposure but have combined the presymptomatic and symptomatic phases (eg., Areekal et al, <sup>4</sup> Sundar and Bhaskar, <sup>21</sup> and Valles et al <sup>34</sup>). This approach may partially account for lower SARs among presymptomatic index cases. Many studies included in our systematic review cautioned that they may not have identified both asymptomatic index cases and asymptomatic household contacts.

Several recent studies <sup>18,35,40,88,96,102-106</sup> examined household SAR by viral variant. We limited our meta-analyses of variants to only those that were reported in 3 or more studies, which only included the B.1.1.7 (a) variant. For the B.1.1.7 (a) variant, SARs ranged from 9.0% to  $42.0\%^{35,40,96,102,103}$  and were reported to be higher compared with SARs for wild-type variants <sup>102</sup> or non-VOCs <sup>104</sup> in Ontario, Canada, and compared with SARs for other lineages in the Netherlands <sup>88</sup> and Oslo, Norway, <sup>103</sup> but lower compared with SARs for the B.1.617.2 ( $\delta$ ) variant in England. <sup>96</sup> These findings are consistent with those reported in a modeling study <sup>105</sup> that estimated that the transmissibility of the B.1.1.7 (a) variant was 43% to 90% higher than that of preexisting variants.

Regarding variants that were examined in fewer than 3 studies for which we did not perform meta-analyses, SARs were also higher for the B.1.351 ( $\beta$ ) or P.1 ( $\gamma$ ) variant (27.2%) and non-VOC variants (23.3%) compared with wild-type variants in Ontario, Canada. <sup>102</sup> Household SARs were higher for contacts with the B.1.427 and B.1.429 ( $\epsilon$ ) variants (35.6%) compared with contacts without these variants in San Francisco, California, <sup>18</sup> whereas no major differences in household SARs were found between individuals with the B.1.526 ( $\gamma$ ) variant and non-VOCs in New York, New York, New York.

Emerging data suggest that vaccination may not only be associated with the prevention of SARS-CoV-2 infections among vaccinated individuals but may also be associated with reductions in transmission to unvaccinated household contacts. <sup>29,107,108</sup> A recent study<sup>29</sup> (published as a preprint) of more than 1 million household contacts in England found that, compared with households in which no individuals received COVID-19 vaccines, household SARs were 40% to 50% lower among

households in which index cases received BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines 21 days or more before receiving a positive test result for SARS-CoV-2. Another study<sup>108</sup> (published as a preprint) of almost 200 000 household members in Scotland reported a 30% reduction in COVID-19 cases among household contacts of health care workers who received BNT162b2 or ChAdOx1 nCoV-19 vaccines at 14 days or more after the second dose compared with household contacts of health care workers who did not receive these vaccines. These findings are consistent with those of a study conducted in Finland<sup>107</sup> that suggested indirect benefit of 8.7% (95% CI, -28.9% to 35.4%) at 2 weeks and 42.9% (95% CI, 22.3%-58.1%) at 10 weeks after the first dose of BNT162b2 or mRNA-1273 vaccines. Results suggesting a possible association between vaccination and reductions in infectiousness include lower disease severity, shorter duration of symptoms, and lower viral load.<sup>109</sup>

#### Limitations

This study has limitations. As described in the previous systematic review and meta-analysis, <sup>1</sup> there was high heterogeneity across studies, which may be attributable to differences in study design (eg, follow-up duration, frequency of testing, and universal and/or symptomatic testing), transmission mitigation strategies after index case diagnosis, household crowding, underlying seroprevalence, and other factors. There was insufficient information to perform meta-analyses of SARs by other VOCs.

# **Conclusions**

This updated systematic review and meta-analysis suggests that the household remains an important site of SARS-CoV-2 transmission, and recent studies have reported higher household SAR estimates compared with the earliest reports. More transmissible variants may be associated with further changes. Recent data suggest that 1 dose of a COVID-19 vaccine may be associated with reductions in the risk of household transmission by up to 50%, <sup>29</sup> potentially supporting the case for universal vaccination and offering a path forward to protect household contacts.

# **ARTICLE INFORMATION**

Accepted for Publication: June 19, 2021.

**Published:** August 27, 2021. doi:10.1001/jamanetworkopen.2021.22240

**Open Access:** This is an open access article distributed under the terms of the CC-BY License. © 2021 Madewell ZJ et al. *JAMA Network Open*.

**Corresponding Author:** Zachary J. Madewell, PhD, Department of Biostatistics, University of Florida, PO Box 117450, Gainesville, FL 32611 (zmadewell@ufl.edu).

**Author Affiliations:** Department of Biostatistics, University of Florida, Gainesville (Madewell, Yang, Longini, Dean); Fred Hutchinson Cancer Research Center, Seattle, Washington (Halloran); Department of Biostatistics, University of Washington, Seattle (Halloran).

**Author Contributions:** Dr Madewell had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Madewell, Longini, Halloran, Dean.

Acquisition, analysis, or interpretation of data: Madewell, Yang, Longini, Halloran.

Drafting of the manuscript: Madewell, Longini, Dean.

Critical revision of the manuscript for important intellectual content: Madewell, Yang, Longini, Halloran.

Statistical analysis: Madewell, Longini, Halloran.

Obtained funding: Longini, Dean.

Supervision: Yang, Halloran, Dean.

**Conflict of Interest Disclosures:** Dr Halloran reported receiving grants from the National Institute of Allergy and Infectious Diseases during the conduct of the study. No other disclosures were reported.

**Funding/Support:** This work was supported by grant RO1-AI139761 from the National Institutes of Health (all authors).

**Role of the Funder/Sponsor:** The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### **REFERENCES**

- 1. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. *JAMA Netw Open*. 2020;3(12):e2031756. doi:10.1001/jamanetworkopen.2020.31756
- 2. Elliott JH, Synnot A, Turner T, et al; Living Systematic Review Network. Living systematic review: 1: introduction—the why, what, when, and how. *J Clin Epidemiol*. 2017;91:23-30. doi:10.1016/j.jclinepi.2017.08.010
- 3. Schwarzer G, Chemaitelly H, Abu-Raddad LJ, Rucker G. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions. *Res Synth Methods*. 2019;10(3): 476-483. doi:10.1002/jrsm.1348
- **4**. Areekal B, Vijayan SM, Suseela MS, et al. Risk factors, epidemiological and clinical outcome of close contacts of COVID-19 cases in a tertiary hospital in southern India. *J Clin Diagn Res.* 2021;15(3):34-37.
- 5. Awang H, Yaacob EL, Syed Aluawi SN, et al. A case-control study of determinants for COVID-19 infection based on contact tracing in Dungun district, Terengganu state of Malaysia. *Infect Dis (Lond)*. 2021;53(3):222-225. doi: 10.1080/23744235.2020.1857829
- **6**. Bender JK, Brandl M, Hohle M, Buchholz U, Zeitlmann N. Analysis of asymptomatic and presymptomatic transmission in SARS-CoV-2 outbreak, Germany, 2020. *Emerg Infect Dis.* 2021;27(4):1159-1163. doi:10.3201/eid2704.204576
- 7. Carazo S, Laliberté D, Villeneuve J, et al. Characterization and evolution of infection control practices among severe acute respiratory coronavirus virus 2 (SARS-CoV-2)-infected healthcare workers in acute-care hospitals and long-term care facilities in Québec, Canada, Spring 2020. *Infect Control Hosp Epidemiol.* 2021;1-9. doi:10.1017/ice. 2021.160
- **8**. Cerami C, Rapp T, Lin FC, et al. High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color. *medRxiv*. Preprint posted online March 12, 2021. doi:10.1101/2021.03.10.21253173
- **9**. Demko ZO, Antar AAR, Blair PW, et al. Clustering of SARS-CoV-2 infections in households of patients diagnosed in the outpatient setting in Baltimore, MD. *Open Forum Infect Dis.* 2021;8(4):ofab121. doi:10.1093/ofid/ofab121
- 10. Gomaa MR, El Rifay AS, Shehata M, et al. Incidence, household transmission, and neutralizing antibody seroprevalence of coronavirus disease 2019 in Egypt: results of a community-based cohort. *PLoS Pathog*. 2021;17 (3):e1009413. doi:10.1371/journal.ppat.1009413
- 11. Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 infections in households—Tennessee and Wisconsin, April–September 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(44):1631-1634. doi:10.15585/mmwr.mm6944e1
- 12. Hu P, Ma M, Jing Q, et al. Retrospective study identifies infection related risk factors in close contacts during COVID-19 epidemic. *Int J Infect Dis.* 2021;103:395-401. doi:10.1016/j.iijid.2020.12.011
- 13. Koureas M, Speletas M, Bogogiannidou Z, et al. Transmission dynamics of SARS-CoV-2 during an outbreak in a Roma community in Thessaly, Greece—control measures and lessons learned. *Int J Environ Res Public Health*. 2021;18(6):2878. doi:10.3390/ijerph18062878
- **14.** Li F, Li YY, Liu MJ, et al. Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infect Dis.* 2021;21(5):617-628. doi:10.1016/S1473-3099(20) 30981-6
- 15. Metlay JP, Haas JS, Soltoff AE, Armstrong KA. Household transmission of SARS-CoV-2. *JAMA Netw Open*. 2021;4(2):e210304. doi:10.1001/jamanetworkopen.2021.0304
- **16.** Miyahara R, Tsuchiya N, Yasuda I, et al. Familial clusters of coronavirus disease in 10 prefectures, Japan, February-May 2020. *Emerg Infect Dis.* 2021;27(3):915-918. doi:10.3201/eid2703.203882
- 17. Ng OT, Marimuthu K, Koh V, et al. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. *Lancet Infect Dis.* 2021;21(3):333-343. doi:10.1016/S1473-3099(20) 30833-1
- **18**. Peng J, Liu J, Mann SA, et al; IDseq Team. Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco. *Clin Infect Dis*. Published online March 31, 2021. doi:10.1093/cid/ciab283

- **19**. Pett J, McAleavey P, McGurnaghan P, et al. Epidemiology of COVID-19 in Northern Ireland, 26 February 2020-26 April 2020. *Epidemiol Infect*. 2021;149:e36. doi:10.1017/S0950268821000224
- **20**. Reid MJA, Prado P, Brosnan H, et al. Assessing testing strategies and duration of quarantine in contact tracing for SARS-CoV-2: a retrospective study of San Francisco's COVID-19 contact tracing program, June-August, 2020. *Open Forum Infect Dis*. Published online April 2, 2021. doi:10.1093/ofid/ofab171
- 21. Sundar V, Bhaskar E. Low secondary transmission rates of SARS-CoV-2 infection among contacts of construction laborers at open air environment. *Germs*. 2021;11(1):128-131. doi:10.18683/germs.2021.1250
- **22**. Tak P, Rohilla J. COVID-19 contact tracing in a tertiary care hospital: a retrospective chart review. *Infect Dis Model*. 2021;6:1-4.
- 23. Tanaka ML, Marentes Ruiz CJ, Malhotra S, et al. Urban household transmission of SARS-CoV-2 during periods of high and low community transmission. *SSRN*. Preprint posted online March 10, 2021. doi:10.2139/ssrn.3801730
- **24**. Tibebu S, Brown KA, Daneman N, Paul LA, Buchan SA. Household secondary attack rate of COVID-19 by household size and index case characteristics. *medRxiv*. Preprint posted online February 25, 2021. doi:10.1101/2021. 02.23.21252287
- 25. Trunfio M, Longo BM, Alladio F, et al. On the SARS-CoV-2 "variolation hypothesis": no association between viral load of index cases and COVID-19 severity of secondary cases. *Front Microbiol*. 2021;12(473):646679. doi:10. 3389/fmicb.2021.646679
- **26**. Wilkinson K, Chen X, Shaw S. Secondary attack rate of COVID-19 in household contacts in the Winnipeg health region, Canada. *Can J Public Health*. 2021;112(1):12-16. doi:10.17269/s41997-020-00451-x
- 27. Wu P, Liu F, Chang Z, et al. Assessing asymptomatic, pre-symptomatic and symptomatic transmission risk of SARS-CoV-2. *Clin Infect Dis.* Published online March 27, 2021. doi:10.1093/cid/ciab271
- **28**. Seto J, Aoki Y, Komabayashi K, et al. Epidemiology of coronavirus disease 2019 in Yamagata Prefecture, Japan, January-May 2020: the importance of retrospective contact tracing. *Jpn J Infect Dis.* Published online March 31, 2021. doi:10.7883/yoken.JJID.2020.1073
- 29. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Impact of vaccination on household transmission of SARS-COV-2 in England. *Khub.net*. Preprint posted online April 28, 2021. https://khub.net/documents/135939561/390853656/Impact+of+vaccination+on+household+transmission+of+SARS-COV-2+in+England.pdf/35bf4bb1-6ade-d3eb-a39e-9c9b25a8122a
- **30**. Kuba Y, Shingaki A, Nidaira M, et al. The characteristics of household transmission during COVID-19 outbreak in Okinawa, Japan from February to May 2020. *Jpn J Infect Dis*. 2021. Published online April 30, 2021.
- **31**. Hsu CY, Wang JT, Huang KC, Fan ACH, Yeh YP, Chen SLS. Household transmission but without the community acquired outbreak of COVID-19 in Taiwan. *J Formos Med Assoc*. 2021;120(Suppl 1):S38-S45.
- **32**. Telle K, Jorgensen SB, Hart R, Greve-Isdahl M, Kacelnik O. Secondary attack rates of COVID-19 in Norwegian families: a nation-wide register-based study. *Eur J Epidemiol*. Published online May 25, 2021. doi:10.1007/s10654-021-00760-6
- **33**. Jashaninejad R, Doosti-Irani A, Karami M, Keramat F, Mirzaei M. Transmission of COVID-19 and its determinants among close contacts of COVID-19 patients. *J Res Health Sci.* 2021;21(2):1-6.
- **34.** Valles X, Roure S, Valerio L, et al. SARS-CoV-2 contact tracing among disadvantaged populations during epidemic intervals should be a priority strategy: results from a pilot experiment in Barcelona. *Public Health*. 2021; 195:132-134. doi:10.1016/j.puhe.2021.04.027
- **35**. Loenenbach A, Markus I, Lehfeld AS, et al. SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021. *Euro Surveill*. 2021; 26(21):2100433. doi:10.2807/1560-7917.ES.2021.26.21.2100433
- **36**. Charbonnier L, Roupret-Serzec J, Caseris M, et al. Contribution of serological rapid diagnostic tests to the strategy of contact tracing in households following SARS-CoV-2 infection diagnosis in children. *Front Pediatr*. 2021;9(217):638502. doi:10.3389/fped.2021.638502
- **37**. Verberk JDM, de Hoog MLA, Westerhof I, et al. Transmission of SARS-CoV-2 within households: a prospective cohort study in the Netherlands and Belgium—interim results. *medRxiv*. Preprint posted online April 26, 2021. doi:10.1101/2021.04.23.21255846
- **38**. Akaishi T, Kushimoto S, Katori Y, et al. COVID-19 transmission in group living environments and households. *Sci Rep.* 2021;11(1):11616. doi:10.1038/s41598-021-91220-4
- **39**. Semakula M, Niragire F, Umutoni A, et al. The secondary transmission pattern of COVID-19 based on contact tracing in Rwanda. *BMJ Glob Health*. 2021;6(6):e004885. doi:10.1136/bmjgh-2020-004885

- **40**. Lyngse FP, Molbak K, Skov RL, et al. Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load: evidence from Danish households. *medRxiv*. Preprint posted online April 19, 2021. doi:10.1101/2021.04. 16 21255459
- **41**. Wang Z, Ma W, Zheng X, Wu G, Zhang R. Household transmission of SARS-CoV-2. *J Infect*. 2020;81(1):179-182. doi:10.1016/j.jinf.2020.03.040
- **42**. Wang X, Zhou Q, He Y, et al. Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China. *Eur Respir J*. 2020;55(6):2000544. doi:10.1183/13993003.00544-2020
- **43**. Yu HJ, Hu YF, Liu XX, et al. Household infection: the predominant risk factor for close contacts of patients with COVID-19. *Travel Med Infect Dis.* 2020;36:101809. doi:10.1016/j.tmaid.2020.101809
- **44**. Li W, Zhang B, Lu J, et al. Characteristics of household transmission of COVID-19. *Clin Infect Dis*. 2020;71(8): 1943-1946. doi:10.1093/cid/ciaa450
- **45**. Lopez Bernal J, Panagiotopoulos N, Byers C, et al. Transmission dynamics of COVID-19 in household and community settings in the United Kingdom. *medRxiv*. Preprint posted online August 22, 2020. doi:10.1101/2020. 08.19.20177188
- **46**. Wu J, Huang Y, Tu C, et al. Household transmission of SARS-CoV-2, Zhuhai, China, 2020. *Clin Infect Dis*. 2020; 71(16):2099-2108. doi:10.1093/cid/ciaa557
- **47**. Sun WW, Ling F, Pan JR, et al. Epidemiological characteristics of 2019 novel coronavirus family clustering in Zhejiang Province. *Zhonqhua Yu Fanq Yi Xue Za Zhi*. 2020;54(0):E027.
- **48**. Bohmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis.* 2020;20(8):920-928. doi:10.1016/S1473-3099(20)30314-5
- **49**. Dong XC, Li JM, Bai JY, et al. Epidemiological characteristics of confirmed COVID-19 cases in Tianjin. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020;41(5):638-641.
- **50**. Hua CZ, Miao ZP, Zheng JS, et al. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. *J Med Virol*. 2020;92(11):2804-2812. doi:10.1002/jmv.26180
- **51**. Chen Y, Wang AH, Yi B, et al. Epidemiological characteristics of infection in COVID-19 close contacts in Ningbo city. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020;41(5):667-671.
- **52.** Xin H, Jiang F, Xue A, et al. Risk factors associated with occurrence of COVID-19 among household persons exposed to patients with confirmed COVID-19 in Qingdao Municipal, China. *Transbound Emerg Dis.* 2021;68(2): 782-788. doi:10.1111/tbed.13743
- **53**. Wu Y, Song S, Kao Q, Kong Q, Sun Z, Wang B. Risk of SARS-CoV-2 infection among contacts of individuals with COVID-19 in Hangzhou, China. *Public Health*. 2020;185:57-59. doi:10.1016/j.puhe.2020.05.016
- **54.** Jing QL, Liu MJ, Zhang ZB, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect Dis.* 2020;20(10):1141-1150. doi:10.1016/S1473-3099(20)30471-0
- **55**. Zhang W, Cheng W, Luo L, et al. Secondary transmission of coronavirus disease from presymptomatic persons, China. *Emerg Infect Dis.* 2020;26(8):1924-1926. doi:10.3201/eid2608.201142
- **56**. Wang X, Pan Y, Zhang D, et al. Basic epidemiological parameter values from data of real-world in mega-cities: the characteristics of COVID-19 in Beijing, China. *BMC Infect Dis.* 2020;20(1):526. doi:10.1186/s12879-020-05251-9
- **57**. Park YJ, Choe YJ, Park O, et al; COVID-19 National Emergency Response Center, Epidemiology and Case Management Team. Contact tracing during coronavirus disease outbreak, South Korea, 2020. *Emerg Infect Dis.* 2020;26(10):2465-2468. doi:10.3201/eid2610.201315
- **58**. Park SY, Kim YM, Yi S, et al. Coronavirus disease outbreak in call center, South Korea. *Emerg Infect Dis*. 2020; 26(8):1666-1670. doi:10.3201/eid2608.201274
- **59**. Liu T, Liang W, Zhong H, et al. Risk factors associated with COVID-19 infection: a retrospective cohort study based on contacts tracing. *Emerg Microbes Infect*. 2020;9(1):1546-1553. doi:10.1080/22221751.2020.1787799
- **60**. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis.* 2020;20(8):911-919. doi:10.1016/S1473-3099(20)30287-5
- **61**. Burke RM, Midgley CM, Dratch A, et al. Active monitoring of persons exposed to patients with confirmed COVID-19—United States, January-February 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(9):245-246. doi:10.15585/mmwr.mm6909e1

- **62**. Luo L, Liu D, Liao X, et al. Contact settings and risk for transmission in 3410 close contacts of patients with COVID-19 in Guangzhou, China: a prospective cohort study. *Ann Intern Med.* 2020;173(11):879-887. doi:10.7326/M20-2671
- **63**. Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nat Commun*. 2021;12(1):1533. doi:10.1038/s41467-021-21710-6
- **64**. Zhuang YL, Zhang YT, Li M, et al. Analysis on the cluster epidemic of coronavirus disease 2019 in Guangdong Province. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2020;54(7):720-725. doi:10.3760/cma.j.cn112150-20200326-00446
- **65**. Cheng HY, Jian SW, Liu DP, Ng TC, Huang WT, Lin HH; Taiwan COVID-19 Outbreak Investigation Team. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. *JAMA Intern Med.* 2020;180(9):1156-1163. doi:10.1001/jamainternmed.2020.2020
- **66**. Kim J, Choe YJ, Lee J, et al. Role of children in household transmission of COVID-19. *Arch Dis Child*. 2021;106 (7):709-711. doi:10.1136/archdischild-2020-319910
- **67**. Zhang JZ, Zhou P, Han DB, et al. Investigation on a cluster epidemic of COVID-19 in a supermarket in Liaocheng, Shandong province. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020;41(12):2024-2028. doi:10.3760/cma.j.cn112338-20200228-00206
- **68**. Patel A, Charani E, Ariyanayagam D, et al. New-onset anosmia and ageusia in adult patients diagnosed with SARS-CoV-2 infection. *Clin Microbiol Infect*. 2020;26(9):1236-1241. doi:10.1016/j.cmi.2020.05.026
- **69**. Boscolo-Rizzo P, Borsetto D, Spinato G, et al. New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects. *Eur Arch Otorhinolaryngol*. 2020;277(9):2637-2640. doi:10.1007/s00405-020-06066-9
- **70**. Rosenberg ES, Dufort EM, Blog DS, et al; New York State Coronavirus 2019 Response Team. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State–March 2020. *Clin Infect Dis*. 2020;71(8):1953-1959. doi:10.1093/cid/ciaa549
- 71. Dattner I, Goldberg Y, Katriel G, et al. The role of children in the spread of COVID-19: using household data from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of children. *PLoS Comput Biol.* 2021;17(2): e1008559. doi:10.1371/journal.pcbi.1008559
- **72**. Lewis NM, Chu VT, Ye D, et al. Household transmission of SARS-CoV-2 in the United States. *Clin Infect Dis*. Published online August 16. 2020. doi:10.1093/cid/ciaa1166
- **73**. van der Hoek W, Backer JA, Bodewes R, et al. The role of children in the transmission of SARS-CoV-2. *Ned Tijdschr Geneeskd*. 2020;164:D5140.
- **74**. Dawson P, Rabold EM, Laws RL, et al. Loss of taste and smell as distinguishing symptoms of coronavirus disease 2019. *Clin Infect Dis.* 2021;72(4):682-685.
- **75**. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Glob Health*. 2020;5(5):e002794. doi: 10.1136/bmjgh-2020-002794
- **76**. Han T. Outbreak investigation: transmission of COVID-19 started from a spa facility in a local community in Korea. *Epidemiol Health*. 2020;42:e2020056. doi:10.4178/epih.e2020056
- 77. Bae S, Kim H, Jung TY, et al. Epidemiological characteristics of COVID-19 outbreak at fitness centers in Cheonan, Korea. *J Korean Med Sci.* 2020;35(31):e288. doi:10.3346/jkms.2020.35.e288
- **78**. Doung-Ngern P, Suphanchaimat R, Panjagampatthana A, et al. Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, Thailand. *Emerg Infect Dis.* 2020;26(11):2607-2616. doi:10.3201/eid2611.203003
- **79**. Fateh-Moghadam P, Battisti L, Molinaro S, et al. Contact tracing during phase I of the COVID-19 pandemic in the province of Trento, Italy: key findings and recommendations. *medRxiv*. Preprint posted online July 29, 2020. doi:10.1101/2020.07.16.20127357
- **80**. Phiriyasart F, Chantutanon S, Salaeh F, et al. Outbreak investigation of coronavirus disease (COVID-19) among Islamic missionaries in southern Thailand, April 2020. *Outbreak Surveill Investiq Rep.* 2020;13(2):48-54.
- **81**. Arnedo-Pena A, Sabater-Vidal S, Meseguer-Ferrer N, et al. COVID-19 secondary attack rate and risk factors in household contacts in Castellon (Spain): preliminary report. *Enfermedades Emergentes*. 2020;19(2):64-70.
- **82**. Malheiro R, Figueiredo AL, Magalhaes JP, et al. Effectiveness of contact tracing and quarantine on reducing COVID-19 transmission: a retrospective cohort study. *Public Health*. 2020;189:54-59. doi:10.1016/j.puhe.2020. 09.012

- **83**. Son H, Lee H, Lee M, et al. Epidemiological characteristics of and containment measures for COVID-19 in Busan, Korea. *Epidemiol Health*. 2020;42:e2020035. doi:10.4178/epih.e2020035
- **84**. Yung CF, Kam KQ, Chong CY, et al. Household transmission of severe acute respiratory syndrome coronavirus 2 from adults to children. *J Pediatr*. 2020;225:249-251. doi:10.1016/j.jpeds.2020.07.009
- **85**. Lee M, Eun Y, Park K, Heo J, Son H. Follow-up investigation of asymptomatic COVID-19 cases at diagnosis in Busan, Korea. *Epidemiol Health*. 2020;42:e2020046. doi:10.4178/epih.e2020046
- **86**. Draper AD, Dempsey KE, Boyd RH, et al. The first 2 months of COVID-19 contact tracing in the northern territory of Australia, March-April 2020. *Commun Dis Intell* (2018). 2020;44:1-10. doi:10.33321/cdi.2020.44.53
- **87**. Teherani MF, Kao CM, Camacho-Gonzalez A, et al. Burden of illness in households with severe acute respiratory syndrome coronavirus 2-infected children. *J Pediatric Infect Dis Soc.* 2020;9(5):613-616. doi:10.1093/jpids/piaa097
- **88**. Lyngse FP, Kirkeby CT, Halasa T, et al. COVID-19 transmission within Danish households: a nationwide study from lockdown to reopening. *medRxiv*. Preprint posted online September 9, 2020. doi:10.1101/2020.09. 09.20191239
- **89**. Islam SS, Noman ASM. Transmission dynamics and contact tracing assessment of COVID-19 in Chattogram, Bangladesh and potential risk of close contacts at different exposure settings. *SSRN*. Preprint posted online October 12, 2020. doi:10.2139/ssrn.3677863
- **90**. Adamik B, Bawiec M, Bezborodov V, et al; MOCOS International Research Group. Bounds on the total number of SARS-CoV-2 infections: the link between severeness rate, household attack rate and the number of undetected cases. *ResearchGate*. Preprint posted online July 29, 2020. doi:10.13140/RG.2.2.30750.77124
- **91.** Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science*. 2020;370(6517):691-697. doi:10.1126/science.abd7672
- **92**. Shah K, Desai N, Saxena D, Mavalankar D, Mishra U, Patel GC. Household secondary attack rate in Gandhinagar district of Gujarat state from western India. *medRxiv*. Preprint posted online September 5, 2020. doi:10.1101/2020. 09.03.20187336
- **93**. Chaw L, Koh WC, Jamaludin SA, Naing L, Alikhan MF, Wong J. Analysis of SARS-CoV-2 transmission in different settings, Brunei. *Emerg Infect Dis.* 2020;26(11):2598-2606. doi:10.3201/eid2611.202263
- **94.** COVID-19 National Emergency Response Center; Epidemiology Case Management Team; Korea Centers for Disease Control and Prevention. Coronavirus disease-19: summary of 2,370 contact investigations of the first 30 cases in the Republic of Korea. *Osong Public Health Res Perspect*. 2020;11(2):81-84. doi:10.24171/j.phrp. 2020.11.2.04
- **95**. Liu R, Han H, Liu F, et al. Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. *Clin Chim Acta*. 2020;505:172-175. doi:10.1016/j.cca.2020. 03.009
- **96.** Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Public Health England; 2021. Technical briefing 14. Accessed June 10, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/991343/Variants\_of\_Concern\_VOC\_Technical\_Briefing\_14.pdf
- **97**. Hou C, Chen J, Zhou Y, et al. The effectiveness of quarantine of Wuhan city against the corona virus disease 2019 (COVID-19): a well-mixed SEIR model analysis. *J Med Virol*. 2020;92(7):841-848. doi:10.1002/jmv.25827
- **98**. Elvik R. Publication bias and time-trend bias in meta-analysis of bicycle helmet efficacy: a re-analysis of Attewell, Glase and McFadden, 2001. *Accid Anal Prev.* 2011;43(3):1245-1251. doi:10.1016/j.aap.2011.01.007
- **99**. Apra C, Caucheteux C, Mensch A, et al; AP-HP/Universities/Inserm COVID-19 Research Collaboration. Predictive usefulness of PCR testing in different patterns of Covid-19 symptomatology—analysis of a French cohort of 12,810 outpatients. *medRxiv*. Preprint posted online June 9, 2020. doi:10.1101/2020.06.07.20124438
- **100**. Alyammahi SK, Abdin SM, Alhamad DW, Elgendy SM, Altell AT, Omar HA. The dynamic association between COVID-19 and chronic disorders: an updated insight into prevalence, mechanisms and therapeutic modalities. *Infect Genet Evol.* 2021;87:104647. doi:10.1016/j.meegid.2020.104647
- **101**. Qiu X, Nergiz AI, Maraolo AE, Bogoch II, Low N, Cevik M. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. *Clin Microbiol Infect*. 2021;27(4):511-519. doi:10.1016/j.cmi.2021.01.011
- **102**. Brown KA, Tibebu S, Daneman N, Schwartz K, Whelan M, Buchan S. Comparative household secondary attack rates associated with B.1.1.7, B.1.351, and P.1 SARS-CoV-2 variants. *medRxiv*. Preprint posted online June 4, 2021. doi:10.1101/2021.06.03.21258302

- **103**. Lindstrom JC, Engebretsen S, Brathen Kristoffersen A, et al. Increased transmissibility of the B.1.1.7 SARS-CoV-2 variant: evidence from contact tracing data in Oslo, January to February 2021. *medRxiv*. Preprint posted online March 30, 2021. doi:10.1101/2021.03.29.21254122
- **104**. Buchan SA, Tibebu S, Daneman N, et al. Increased household secondary attacks rates with variant of concern SARS-CoV-2 index cases. *Clin Infect Dis*. Published online June 9, 2021. doi:10.1093/cid/ciab496
- **105**. Davies NG, Abbott S, Barnard RC, et al; CMMID COVID-19 Working Group; COVID-19 Genomics UK (COG-UK) Consortium. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;372 (6538):eabg3055. doi:10.1126/science.abg3055
- **106**. Thompson CN, Hughes S, Ngai S, et al. Rapid emergence and epidemiologic characteristics of the SARS-CoV-2 B.1.526 variant—New York City, New York, January 1-April 5, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70 (19):712-716. doi:10.15585/mmwr.mm7019e1
- **107**. Salo J, Hagg M, Kortelainen M, et al. The indirect effect of mRNA-based Covid-19 vaccination on unvaccinated household members. *medRxiv*. Preprint posted online May 29, 2021. doi:10.1101/2021.05.27.21257896
- **108**. Shah ASV, Gribben C, Bishop J, et al. Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households. *medRxiv*. Preprint posted online March 21, 2021. doi:10.1101/2021. 03.11.21253275
- **109**. Richterman A, Meyerowitz EA, Cevik M. Indirect protection by reducing transmission: ending the pandemic with SARS-CoV-2 vaccination. *Open Forum Infect Dis.* Published online May 19, 2021. doi:10.1093/ofid/ofab259

#### SUPPLEMENT.

**eReferences** 

eTable 1. Description of Studies Published From October 20, 2020, to June 17, 2021 eTable 2. Household Secondary Attack Rates for SARS-CoV-2, Restricted to Studies With a More Uniform Design eFigure. Household Secondary Attack Rates of SARS-CoV-2 for B.1.1.7 (a) Variant